Skip to main content
    G

    Gilead Sciences Inc (GILD)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $167.58
    -0.50 (-0.30%)

    Market Cap: $208.48B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Gilead Sciences Inc (GILD) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Gilead Sciences (GILD) is expected to report earnings on Feb 8, 2027. In the quarter ended Sep 30, 2026, Gilead Sciences reported EPS of $2.55, above the $2.17 estimate. It beat the EPS estimate in each of the last 11 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    75%(30/40)
    Avg Surprise
    +5.43%
    Streak
    11 Q

    Upcoming Estimates

    Reports Feb 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$1.22
    Range$0.90 - $2.28
    23 analysts
    Revenue Consensus
    $8.51B
    Range$8.09B - $8.96B
    20 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$2.14
    Range$1.90 - $2.26
    6 analysts
    EPS Revisions
    1
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$2.30-7.1%
    60d ago$2.30-7.1%
    30d ago$2.31-7.3%
    7d ago$2.17-1.6%
    Current$2.14
    Revenue Consensus
    $7.44B
    Range$7.28B - $7.58B
    4 analysts

    Next Report

    GILD has an expected report date of Feb 8, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 34.4% below the $1.86 reported for the quarter ended Dec 31, 2025.

    GILD Earnings Call

    The latest GILD earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, GILD beat 30 and missed 10. Revenue for the quarter ended Sep 30, 2026 was $8.30B, up 6.8% from $7.77B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$2.55$2.17$1.99 - $2.36+17.51%Beat+3.2%225 up, 2 downOct 29, 2026$8.30B
    Jun 30, 2026-$6.75-$7.07-$7.93 - -$6.40+4.53%Beat-435.8%238 up, 4 downAug 3, 2026$7.80B
    Mar 31, 2026$2.03$1.91$1.74 - $2.06+6.28%Beat+12.2%245 up, 6 downMay 7, 2026$6.96B
    Dec 31, 2025$1.86$1.81$1.60 - $2.16+2.76%Beat-2.1%211 up, 10 downFeb 10, 2026$7.92B
    Sep 30, 2025$2.47$2.14$1.96 - $2.37+15.42%Beat+22.3%224 up, 6 downOct 30, 2025$7.77B
    Jun 30, 2025$2.01$1.95$1.86 - $2.05+3.08%Beat0.0%239 up, 3 downAug 7, 2025$7.08B
    Mar 31, 2025$1.81$1.78$1.60 - $2.11+1.69%BeatN/A171 up, 4 downApr 24, 2025$6.67B
    Dec 31, 2024$1.90$1.70$1.13 - $2.16+11.73%Beat+10.5%202 up, 3 downFeb 11, 2025$7.57B
    Sep 30, 2024$2.02$1.55$1.33 - $1.92+30.32%Beat-11.8%204 up, 0 downNov 6, 2024$7.54B
    Jun 30, 2024$2.01$1.60$1.36 - $1.80+25.63%Beat+50.0%227 up, 0 downAug 8, 2024$6.95B
    Mar 31, 2024-$1.32-$1.52-$1.86 - -$1.14+13.16%Beat-196.4%150 up, 3 downApr 25, 2024$6.69B
    Dec 31, 2023$1.72$1.76$1.59 - $2.04-2.27%Miss+3.0%233 up, 4 downFeb 6, 2024$7.11B
    Sep 30, 2023$2.29$1.92$1.62 - $1.97+19.27%Beat+20.5%223 up, 3 downNov 7, 2023$7.05B
    Jun 30, 2023$1.34$1.64$1.47 - $1.88-18.29%Miss-15.2%230 up, 1 downAug 3, 2023$6.60B
    Mar 31, 2023$1.37$1.54$1.24 - $1.97-11.04%Miss-35.4%224 up, 2 downApr 27, 2023$6.35B
    Dec 31, 2022$1.67$1.51$1.16 - $1.72+10.60%Beat+142.0%223 up, 2 downFeb 2, 2023$7.39B
    Sep 30, 2022$1.90$1.43$1.16 - $1.75+32.87%Beat-28.3%232 up, 5 downOct 27, 2022$7.04B
    Jun 30, 2022$1.58$1.52$1.29 - $1.73+3.95%Beat-15.5%227 up, 2 downAug 2, 2022$6.26B
    Mar 31, 2022$2.12$1.81$1.38 - $2.17+17.13%Beat+1.9%215 up, 1 downApr 28, 2022$6.59B
    Dec 31, 2021$0.69$1.59$1.21 - $2.14-56.60%Miss-68.5%219 up, 0 downFeb 1, 2022$7.24B
    Sep 30, 2021$2.65$1.78$1.49 - $2.16+48.88%Beat+25.6%20N/AOct 28, 2021$7.42B
    Jun 30, 2021$1.87$1.75$1.50 - $1.97+6.86%Beat+68.5%22N/AJul 29, 2021$6.22B
    Mar 31, 2021$2.08$2.11$1.71 - $2.57-1.42%Miss+23.8%21N/AApr 29, 2021$6.42B
    Dec 31, 2020$2.19$2.15$2.02 - $2.33+1.86%Beat+68.5%19N/AFeb 4, 2021$7.42B
    Sep 30, 2020$2.11$1.89$1.65 - $2.65+11.64%Beat+20.6%24N/AOct 28, 2020$6.58B
    Jun 30, 2020$1.11$1.45$1.13 - $1.84-23.45%Miss-39.0%24N/AJul 30, 2020$5.14B
    Mar 31, 2020$1.68$1.56$1.44 - $1.82+7.69%Beat-4.5%24N/AApr 30, 2020$5.55B
    Dec 31, 2019$1.30$1.67$1.46 - $1.85-22.16%Miss-9.7%24N/AFeb 4, 2020$5.88B
    Sep 30, 2019$1.75$1.73$1.53 - $1.92+1.16%Beat-4.9%23N/AOct 24, 2019$5.60B
    Jun 30, 2019$1.82$1.71$1.50 - $1.89+6.43%Beat-4.7%24N/AJul 30, 2019$5.68B
    Mar 31, 2019$1.76$1.60$1.41 - $1.73+10.00%Beat+18.9%24N/AMay 2, 2019$5.28B
    Dec 31, 2018$1.44$1.69$1.44 - $2.13-14.79%Miss-19.1%22N/AFeb 4, 2019$5.79B
    Sep 30, 2018$1.84$1.63$1.55 - $1.86+12.88%Beat-18.9%21N/AOct 25, 2018$5.60B
    Jun 30, 2018$1.91$1.56$1.46 - $1.70+22.44%Beat-25.4%20N/AJul 25, 2018$5.65B
    Mar 31, 2018$1.48$1.67$1.47 - $1.86-11.38%Miss-33.6%21N/AMay 1, 2018$5.09B
    Dec 31, 2017$1.78$1.67$1.29 - $2.00+6.59%Beat-34.1%22N/AFeb 6, 2018$5.95B
    Sep 30, 2017$2.27$2.13$1.92 - $2.30+6.57%Beat-17.5%22N/AOct 26, 2017$6.51B
    Jun 30, 2017$2.56$2.17$1.91 - $2.34+17.97%Beat-16.9%19N/AJul 26, 2017$7.14B
    Mar 31, 2017$2.23$2.28N/A-2.19%Miss-26.4%N/AN/AMay 2, 2017$6.50B
    Dec 31, 2016$2.70$2.60N/A+3.85%Beat-18.7%N/AN/AFeb 7, 2017$7.32B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $8.15, up 76.8% from the year before. It was $11.56 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$8.15+76.8%
    Dec 31, 2024$4.61-31.4%
    Dec 31, 2023$6.72-7.6%
    Dec 31, 2022$7.27N/A
    Dec 31, 2021$7.29+2.8%
    Dec 31, 2020$7.09+6.9%
    Dec 31, 2019$6.63N/A
    Dec 31, 2018$6.67-24.5%
    Dec 31, 2017$8.84-23.5%
    Dec 31, 2016$11.56N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,700 words across 18 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,73318
    2026Q2Jun 30, 20267,64119
    2026Q1Mar 31, 20268,52919
    2025Q4Dec 31, 20258,69017
    2025Q3Sep 30, 20258,00622
    2025Q2Jun 30, 20257,91716
    2025Q1Mar 31, 20259,21023
    2024Q4Dec 31, 20244,01717

    2026Q3 Earnings Call

    Opening remarks

    Jacquie Ross Senior Vice President, Treasurer and Head of Investor Relations Thank you, Rebekah. Just after market closed today, we issued a press release with earnings results for the third quarter of 2026. The press release, slides and supplementary data are available on the Investors section of our website at gilead.com. The speakers on today's call will be our Chairman and Chief Executive Officer, Daniel O'Day; our Chief Commercial and Corporate Affairs Officer, Johanna Mercier; our Chief Medical Officer, Dietmar Berger; and our Chief Financial Officer, Andrew Dickinson. After that, we'll open the call to Q&A, where the team will be joined by Cindy Perettie, the Executive Vice President of Kite. Let me remind you that we will be making forward-looking statements. Please refer to Slide 2 regarding the risks and uncertainties relating to forward-looking statements that could cause actual results to differ materially. With that, I'll turn the call over to Dan.

    Daniel O'Day Chairman and Chief Executive Officer Thank you, Jacquie, and thanks, everyone, for joining us on today's call. Gilead delivered an exceptional third quarter that highlights the strength, breadth and durability of the business. Third quarter base business sales were up 16% year-over-year, Gilead's strongest growth in more than a decade, driven by Biktarvy, Descovy and Yeztugo in HIV, Trodelvy in metastatic breast cancer, and Livdelzi in PBC. At the same time, we continue to advance our diverse pipeline as we prepare for the next phase of launches. In HIV, we continue to lead across treatment and prevention. In the third quarter, HIV sales grew 18% year-over-year. Biktarvy achieved an all-time high U.S. market share, and we had a modest initial contribution from Bixlenvo, which launched in August. HIV prevention sales nearly doubled year-over-year. As expected, Yeztugo has rapidly established itself as the leading long-acting injectable option for HIV prevention. Yeztugo and Descovy for PrEP combined have 50% market share today and a $4 billion annual run rate. As Dietmar will cover later, we believe we have the most comprehensive and diverse HIV pipeline in the industry as well as in Gilead's history. Across daily and long-acting dosing, we are advancing a portfolio that will deliver new options for many years to come. The most near-term example is islatravir plus lenacapavir. We expect to file this year, and, if approved, this would be the first once-weekly oral treatment regimen for virally suppressed people with HIV. In Oncology, Trodelvy delivered another very strong quarter. Sales were up 42% year-over-year, and with growing demand across triple-negative and HR-positive/HER2-negative metastatic breast cancer, Trodelvy reached an approximately $2 billion annual run rate. In the third quarter, we received European approval of Trodelvy in combination with pembrolizumab for first-line PD-L1-positive metastatic triple-negative breast cancer, extending Trodelvy's benefits to patients earlier in treatment.

    Frequently Asked Questions About GILD

    When is Gilead Sciences's next earnings date?

    Gilead Sciences's next earnings report is expected for Feb 8, 2027.

    Did GILD beat earnings estimates last quarter?

    Yes. Gilead Sciences reported EPS of $2.55 for the quarter ended Sep 30, 2026, above the $2.17 estimate, a 17.51% surprise.

    What EPS do analysts expect from GILD next quarter?

    The consensus EPS estimate for Gilead Sciences for the quarter ending Dec 31, 2026 is $1.22 from 23 analysts, with estimates from $0.90 to $2.28.

    How often does GILD beat earnings estimates?

    Gilead Sciences beat the EPS estimate in each of the last 11 quarters, with an average surprise of +12.01%.